Skip to content
value.today
Lucid Diagnostics Inc. logo

Lucid Diagnostics Inc.

🇺🇸 New York, New York, USABiotechnologyFounded 2018

Lucid Diagnostics Inc. is listed today as Lucid Diagnostics Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Lucid Diagnostics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2023$5 MPrivate placement after listing$2 to $10 million

Lucid Diagnostics Inc.: Private sale, Oct 2023

Investors in this round

2 investors had bought by the notice of Nov 1, 2023: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
$250,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis M McGrath · Executive Officer
  • Lishan Aklog · Executive Officer, Director
  • Michael A Gordon · Executive Officer
  • Shaun M O'Neil · Executive Officer
  • Debra M White · Director
  • Jacque J Sokolov · Director
  • James L Cox · Director
  • Ronald M Sparks · Director
  • Stanley L Lapidus · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Dennis M. McGrath, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 1, 2023. Read the notice at the SEC.

equitySEC
Mar 2023$14 MPrivate placement after listing$10 to $50 million

Lucid Diagnostics Inc.: Private sale, Mar 2023

Investors in this round

4 investors had bought by the notice of Mar 22, 2023: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $20 M offered; $6 M still to sell
Smallest investment taken
$250,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis M McGrath · Executive Officer
  • Lishan Aklog · Executive Officer, Director
  • Michael A Gordon · Executive Officer
  • Shaun M O'Neil · Executive Officer
  • Debra M White · Director
  • Jacque J Sokolov · Director
  • James L Cox · Director
  • Ronald M Sparks · Director
  • Stanley L Lapidus · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Dennis M. McGrath, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 22, 2023. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Lucid Diagnostics Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2023).

    SEC Form D · Nov 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2023

That is all the official record says: Lucid Diagnostics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Lucid Diagnostics Inc. are on record.

Investors#

No investor of Lucid Diagnostics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Lucid Diagnostics Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Lucid Diagnostics Inc.
NameRoleNamed in
Dennis M McGrathExecutive officerNov 2023
Lishan AklogExecutive officerNov 2023
Michael A GordonExecutive officerNov 2023
Shaun M O'NeilExecutive officerNov 2023
Debra M WhiteDirectorNov 2023
Jacque J SokolovDirectorNov 2023
James L CoxDirectorNov 2023
Lishan AklogDirectorNov 2023
Ronald M SparksDirectorNov 2023
Stanley L LapidusDirectorNov 2023

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.